Emcure Pharmaceuticals Limited (NSE:EMCURE)

India flag India · Delayed Price · Currency is INR
1,455.50
+1.00 (0.07%)
At close: Feb 27, 2026
47.36%
Market Cap 275.92B
Revenue (ttm) 88.50B
Net Income (ttm) 8.70B
Shares Out 189.57M
EPS (ttm) 45.90
PE Ratio 31.71
Forward PE 25.09
Dividend 3.00 (0.21%)
Ex-Dividend Date n/a
Volume 960,331
Average Volume 172,871
Open 1,452.00
Previous Close 1,454.50
Day's Range 1,434.60 - 1,489.80
52-Week Range 889.00 - 1,585.60
Beta n/a
RSI 47.26
Earnings Date Feb 4, 2026

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the develop... [Read more]

Sector Healthcare
Founded 1981
Employees 6,731
Stock Exchange National Stock Exchange of India
Ticker Symbol EMCURE
Full Company Profile

Financial Performance

In fiscal year 2025, Emcure Pharmaceuticals's revenue was 78.96 billion, an increase of 18.59% compared to the previous year's 66.58 billion. Earnings were 6.81 billion, an increase of 36.76%.

Financial Statements

News

There is no news available yet.